ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
ImmunityBio stock gains more than 7% after completing two programs, showing scalable production of M-ceNK NK cells and early ...
A unique and reliable approach for inducing NK cells from iPSCs (iNK) in a completely feeder-free environment was designed in this study. After 35 days, the cell proportion of CD3-CD56 + iNK Cells ...
Cancer immunotherapy has been transformed by engineered T cells, but those bespoke treatments are slow, expensive, and out of reach for many patients who need help quickly. A new way to generate vast ...
Myocardial infarction research reveals immune-driven cardiac damage. Learn how targeting NK cells could improve heart ...
Cell therapy first reached patients as treatments for cancer. Artiva Biotherapeutics is part of a growing group of companies working to bring cell therapy to autoimmune disease, and its IPO has raised ...
Natural Killer (NK) cells are vital immune defenders that target and destroy cancer cells. However, in aging and cancer patients, NK cells often become "senescent"—losing their effectiveness due to ...
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
SENTI-202, an allogeneic CAR NK cell therapy, offers a pre-manufactured option for aggressive cancers like AML, overcoming delays associated with autologous CAR T-cell therapies. The therapy's unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results